%201.png)
Key Takeaways:
- One year after publication, the AAP Clinical Report continues to influence pediatric care for children with unexplained GDD/ID.
- The report helped align pediatric care with genomic medicine best practices by supporting earlier use of exome and genome sequencing.
- Earlier molecular diagnosis can inform care planning, family support, and access to emerging therapies.
- The report remains an important milestone in the evolution of precision medicine for neurodevelopmental disorders.
Why the AAP Clinical Report Matters One Year Later
One year after the American Academy of Pediatrics (AAP) published its Clinical Report, Genetic Evaluation of the Child With Intellectual Disability or Global Developmental Delay, its impact continues to shape pediatric care.
The report represented a landmark shift by recommending exome sequencing (ES) with chromosomal microarray (CMA), or genome sequencing (GS), as first-tier testing options for children with unexplained global developmental delay (GDD) and intellectual disability (ID).
The guidance aligned pediatric primary care recommendations with existing guidance from the American College of Medical Genetics and Genomics (ACMG), and reinforced the growing role of genomic medicine in pediatric care. One year later, the report remains an important milestone in the movement toward earlier diagnosis, precision medicine, and improved access to genomic testing.
Impact on Clinical Practice
Over the past year, the report has accelerated awareness among pediatricians and developmental specialists that genetic testing should be considered early in the diagnostic journey rather than as a last resort. By elevating ES/GS to first-tier status, the AAP emphasized the importance of pursuing a molecular diagnosis as part of routine evaluation for developmental delay.
The report also reframed the role of other tests:
- Chromosomal microarray remains a first-tier tool, used alongside exome sequencing.
- Fragile X testing shifted to a more targeted second-tier role in many patients.
- Broad metabolic testing is now recommended primarily when specific clinical indicators are present.
This change reflects a broader movement toward precision diagnostics, where testing strategies are informed by diagnostic yield, clinical utility, and cost-effectiveness.
Implications for Patients and Families
The most meaningful impact is on children and families seeking answers. Earlier access to genomic testing can:
- Increase the likelihood of obtaining a diagnosis.
- Inform prognosis and medical management.
- Guide surveillance for associated health risks.
- Enable more accurate recurrence risk counseling.
- Connect families with syndrome-specific resources, support organizations, and clinical trials.
- Identify patients who may benefit from emerging targeted therapies.
For many families, a genetic diagnosis provides clarity after years of uncertainty and can significantly influence care planning.
Impact on the Rare Disease Ecosystem
The report arrived during a period of rapid growth in rare disease therapeutics and precision medicine. As more gene-specific treatments enter development and clinical practice, establishing an accurate molecular diagnosis becomes increasingly important.
By endorsing genomic sequencing earlier in the diagnostic pathway, the AAP reinforced the concept that diagnosis is not simply an endpoint—it is often the gateway to treatment opportunities, research participation, and long-term care planning.
Looking Ahead
One year after publication, the AAP Clinical Report remains one of the most influential pediatric genetics policy updates in recent years. Its endorsement of first-tier genomic sequencing for unexplained GDD/ID reflects the continued evolution of pediatric care toward earlier diagnosis, greater precision, and improved access to genomic medicine.
As evidence continues to accumulate and therapeutic options expand, the report is likely to be remembered as a key milestone in the integration of genomic testing into mainstream pediatric practice.
